Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integration of clinical phenoms and metabolomics facilitates precision medicine for lung cancer.

Cell biology and toxicology - 1 May 2024

Yan Furong, Liu Chanjuan, Song Dongli, Zeng Yiming, Zhan Yanxia, Zhuang Xibing, Qiao Tiankui, Wu Duojiao, Cheng Yunfeng, Chen Hao

Abstract excerpt

Lung cancer is a common malignancy that is frequently associated with systemic metabolic disorders. Early detection is pivotal to survival improvement. Although blood biomarkers have been used in its early diagnosis, missed diagnosis and misdiagnosis still exist due to the heterogeneity of lung cancer. Integration of multiple biomarkers or trans-omics results can improve the accuracy and reliability for lung...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lipidomics

Share to Lipids

Share to Lung Neoplasms

Share to Metabolome

Share to Metabolomics

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 38691184
DOI: 10.1007/s10565-024-09861-w
PMCID: PMC11063108

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integration of clinical phenoms and metabolomics facilitates precision medicine for lung cancer.PMID 38691184Read ↗

Integrative metabolomics and transcriptomics analysis reveals novel therapeutic vulnerabilities in lung cancerSemantic proximity Read ↗

Histological and genetic features and therapeutic responses of lung cancers explored via the global analysis of their metabolome profile.Semantic proximity Read ↗

Novel Lipidomes Profile and Clinical Phenotype Identified in Pneumoconiosis PatientsSemantic proximity Read ↗

Multi-omic profiling of squamous cell lung cancer identifies metabolites and related genes associated with squamous cell carcinomaSemantic proximity Read ↗

Evolutionary metabolic landscape from preneoplasia to invasive lung adenocarcinomaSemantic proximity Read ↗

Targeted metabolomic profiling as a tool for diagnostics of patients with non- small-cell lung cancerSemantic proximity Read ↗

Metabolomic profiling reveals distinct metabolic patterns and a potential circulating biomarker in pre-COPDSemantic proximity Read ↗

Multi-omics profiling with untargeted proteomics for blood-based early detection of lung cancerSemantic proximity Read ↗

Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment.Semantic proximity Read ↗

Unraveling the Rewired Metabolism in Lung Cancer Using Quantitative NMR Metabolomics.Semantic proximity Read ↗

Data Driven Identification of Plasma Metabolite Clusters and Metabolites of Interest for Potential Detection of Early Stage Non-Small Cell Lung Cancer Cases Versus Cancer-Free ControlsSemantic proximity Read ↗

Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.